Merck & Co., Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +2.5%
EBITDA: -28.0%
EBIT: -14.5%
EPS: -48.3%
Free cash flow: -17.2%
Operating cash flow: -14.3%

Forward estimates

Revenue: +4.4%
EBITDA: +57.2%
EPS: +153.6%

Three-year CAGR

Revenue: +3.1%
EBITDA: +9.9%
EBIT: +8.7%
Net income: +7.9%
EPS: +8.4%
Free cash flow: -5.6%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.